BioBTX signs a €20.8m EU Innovation Fund grant for its Delfzijl plastic to aromatics plant
BioBTX has signed a €20.8 million EU Innovation Fund grant with CINEA for PETRA, its first commercial plant turning mixed plastic waste into aromatics.
BioBTX has signed a grant agreement worth €20.8 million under the European Union Innovation Fund for PETRA, its first commercial scale plant at Chemie Park Delfzijl in the north of the Netherlands. The agreement was signed with CINEA, the European Climate, Infrastructure and Environment Executive Agency, and was reported on 16 October 2026 by the Dutch industrial title Industrielinqs and in a Dealroom news note the same day. Neither the company nor the agency published executive comment alongside the signature.
PETRA is the first industrial application of the company's Integrated Catalytic Cracking Process, which it shortens to ICCP. The process runs in two stages. A thermal step breaks mixed polymers down into smaller hydrocarbons, then a catalytic step pushes the output towards aromatics. The target feedstock is the fraction that mechanical recycling handles badly or not at all, meaning mixed, contaminated and multilayer plastics. The plant is sized for roughly 20,000 tonnes of that waste a year and roughly 10,000 tonnes a year of aromatic rich oil containing benzene, toluene and xylenes, the three molecules behind the BTX in the company name, alongside about 8,000 tonnes of by-products.
The grant lands on top of a project the company had already committed to. BioBTX took a positive final investment decision in July 2026 on a build worth more than €80 million. BlueAlp licenses the first pyrolysis stage and is handling engineering, design and manufacture of the modules, which are being built in Eindhoven and are due to ship to Delfzijl from December 2026. Construction on the Delfzijl site is scheduled to start in early 2027, with start-up expected by the middle of 2028. The company puts the lifecycle greenhouse gas reduction against fossil aromatics at 70 to 80 per cent.
Aromatics are the quiet half of the chemicals industry. Benzene, toluene and xylenes sit upstream of plastics, resins, coatings, solvents and a long list of intermediates, and almost all of the global supply comes from oil and gas. There is no drop-in biological route at scale, which is why a plant producing renewable aromatics from waste is treated as a first of a kind rather than another recycling line. What a signed Innovation Fund agreement does not do is prove the process at commercial duty. On the company's own schedule that evidence arrives in 2028, and the grant is a condition of building the thing that will produce it, not a substitute.
Why it matters for AgTech founders: the Innovation Fund is the instrument most often overlooked by founders building first of a kind production assets in biologicals, fermentation, biobased materials and ag processing, and this is what a successful application looks like from the outside. Three things stand out. First, the sequence. The final investment decision came in July, before the grant was signed in October, which means the project was financeable without the grant and the grant improved it. Grant committees read that as de-risking, and founders who wait for public money to unlock private money usually get neither. Second, the size relative to the build. €20.8 million against more than €80 million is roughly a quarter, which is the realistic shape of this kind of support. It changes a plant's return, it does not pay for the plant, and a model that assumes otherwise will not survive a diligence call. Third, the scope. BioBTX licensed the pyrolysis stage from BlueAlp rather than inventing it, and kept its own novel step, the catalytic conversion to aromatics, as the thing it owns. For an ag founder facing a first commercial plant, the honest question is which unit operations are genuinely yours and which you are rebuilding out of habit, because every one you license shortens the build and narrows what the grant has to cover. The last point is about patience. This company raised more than €80 million for a plant that will start up in 2028 on technology it has been maturing for years, which is the real clock on first of a kind infrastructure, and it is worth setting investor expectations against it before the term sheet rather than after.
BioBTX signs a €20.8m EU Innovation Fund grant for its Delfzijl plastic to aromatics plant
The Dutch company now has a signed grant agreement, a final investment decision taken in July and a construction window that opens in early 2027. The plant still has to run.
BioBTX has signed a grant agreement worth €20.8 million under the European Union Innovation Fund for PETRA, its first commercial scale plant at Chemie Park Delfzijl in the north of the Netherlands. The agreement was signed with CINEA, the European Climate, Infrastructure and Environment Executive Agency, and was reported on 16 October 2026 by the Dutch industrial title Industrielinqs and in a Dealroom news note the same day. Neither the company nor the agency published executive comment alongside the signature.
PETRA is the first industrial application of the company's Integrated Catalytic Cracking Process, which it shortens to ICCP. The process runs in two stages. A thermal step breaks mixed polymers down into smaller hydrocarbons, then a catalytic step pushes the output towards aromatics. The target feedstock is the fraction that mechanical recycling handles badly or not at all, meaning mixed, contaminated and multilayer plastics. The plant is sized for roughly 20,000 tonnes of that waste a year and roughly 10,000 tonnes a year of aromatic rich oil containing benzene, toluene and xylenes, the three molecules behind the BTX in the company name, alongside about 8,000 tonnes of by-products.
The grant lands on top of a project the company had already committed to. BioBTX took a positive final investment decision in July 2026 on a build worth more than €80 million. BlueAlp licenses the first pyrolysis stage and is handling engineering, design and manufacture of the modules, which are being built in Eindhoven and are due to ship to Delfzijl from December 2026. Construction on the Delfzijl site is scheduled to start in early 2027, with start-up expected by the middle of 2028. The company puts the lifecycle greenhouse gas reduction against fossil aromatics at 70 to 80 per cent.
Aromatics are the quiet half of the chemicals industry. Benzene, toluene and xylenes sit upstream of plastics, resins, coatings, solvents and a long list of intermediates, and almost all of the global supply comes from oil and gas. There is no drop-in biological route at scale, which is why a plant producing renewable aromatics from waste is treated as a first of a kind rather than another recycling line. What a signed Innovation Fund agreement does not do is prove the process at commercial duty. On the company's own schedule that evidence arrives in 2028, and the grant is a condition of building the thing that will produce it, not a substitute.
Why it matters for AgTech founders: the Innovation Fund is the instrument most often overlooked by founders building first of a kind production assets in biologicals, fermentation, biobased materials and ag processing, and this is what a successful application looks like from the outside. Three things stand out. First, the sequence. The final investment decision came in July, before the grant was signed in October, which means the project was financeable without the grant and the grant improved it. Grant committees read that as de-risking, and founders who wait for public money to unlock private money usually get neither. Second, the size relative to the build. €20.8 million against more than €80 million is roughly a quarter, which is the realistic shape of this kind of support. It changes a plant's return, it does not pay for the plant, and a model that assumes otherwise will not survive a diligence call. Third, the scope. BioBTX licensed the pyrolysis stage from BlueAlp rather than inventing it, and kept its own novel step, the catalytic conversion to aromatics, as the thing it owns. For an ag founder facing a first commercial plant, the honest question is which unit operations are genuinely yours and which you are rebuilding out of habit, because every one you license shortens the build and narrows what the grant has to cover. The last point is about patience. This company raised more than €80 million for a plant that will start up in 2028 on technology it has been maturing for years, which is the real clock on first of a kind infrastructure, and it is worth setting investor expectations against it before the term sheet rather than after.
